Overall Survival Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With HR+/HER2– Metastatic Breast Cancer

Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.

Video Player is loading.
Current Time 0:00
Duration 20:11
Loaded: 0%
Stream Type LIVE
Remaining Time 20:11
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
x